Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb randomized placebo-controlled dose-ranging study of JNJ-77242113 in moderately to severely active ulcerative colitis
CTR20233866Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of icotrokinra in autoimmune colitis, sponsored by Janssen Pharmaceutical. Started Nov 2023; status: completed.
02
Drugs
icotrokinra
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20233866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233866.